EC Number   |
Application |
Reference |
|---|
   1.6.2.4 | analysis |
96-well plate format assay to follow cytochrome c reduction |
764770 |
| 1.6.2.4 | biotechnology |
the enzyme is displayed on the cell surface of Escherichia coli, creating a whole-cell biocatalyst for oxidoreduction of various substrates |
676967 |
| 1.6.2.4 | degradation |
coexpression of CPR and P450 cytochromes CYP6AE14 or CYP9A12 of Helicoverpa armigera in Pichia pastoris. CYP6AE14 is not involved in gossipol degradation, but CYP9A12 takes part in gossipol metabolism |
765505 |
| 1.6.2.4 | medicine |
a Saccharomyces cerevisiae strain is engineered to express seven heterologous enzymes (Papaper somniferum norcoclaurine 6-O-methyltransferase (Ps6OMT), Papaver somniferum 3'-hydroxy-N-methylcoclaurine 4'-O-methyltransferase 2 (Ps4'OMT), Papapver somniferum coclaurine N-methyltransferase (PsCNMT), Papaver somniferum berberine bridge enzyme (PsBBE), Thalictrum flavum scoulerine 9-O-methyltransferase (TfS9OMT), Thalictrum flavum canadine synthase (TfCAS), and Arabidopsis thaliana cytochrome P450 reductase 1 (CPR)), resulting in protoberberine alkaloid production from a simple benzylisoquinoline alkaloid precursor. A number of strategies are implemented to improve flux through the pathway, including enzyme variant screening, genetic copy number variation, and culture optimization. This leads to an over 70-fold increase in canadine titer up to 1.8 mg/l. Increased canadine titers enable extension of the pathway to produce berberine, a major constituent of several traditional medicines in a microbial host. This strain is viable at pilot scale |
743234 |
| 1.6.2.4 | medicine |
manifesting heterozygosity is a possible feature of P450 oxidoreductase deficiency |
687959 |
| 1.6.2.4 | medicine |
medical research, expression systems allows examinations on the activation of promutagenic drugs |
659978 |
| 1.6.2.4 | medicine |
nitrofurantoin-induced redox cycling and subsequent generation of reactive oxygen intermediates are not sufficient to mediate cytotoxicity. Cytochrome P450 reductase is not a determinant of sensitivity to redox-active chemotherapeutic agents |
686876 |
| 1.6.2.4 | medicine |
presence of quercetin and (-)-epigallocatechin gallate in human diet may increase P-450 reductase activity during doxorubicin therapy (antitumour drug) with subsequent increased risk of toxicity |
671680 |
| 1.6.2.4 | medicine |
the POR genotype contributes to breast cancer risk among African American women |
685942 |
| 1.6.2.4 | medicine |
triple mutant L86F/L219F/P456A or a double mutant L86F/L219F enzyme will serve as a good model of mosquito CYPOR in future structural studies and in the development of new antimalarial agents |
684727 |
